Nephrotoxicity and Kidney Fibrosis Due to Gentamicin in Wistar Rats
DOI:
https://doi.org/10.36408/mhjcm.v10i2.909Keywords:
Gentamicin, Renal Fibrosis, Nephrotoxic, Wistar RatAbstract
Background : Gentamicin is an aminoglycoside used as a treatment for various infections. One of the side effects reported on the use of gentamicin is nephrotoxic. However, there are still many uses of gentamicin that have not been precisely indicated.
Objective : To analyze the nephrotoxic effects leading to renal fibrosis due to gentamicin induction in Wistar rats.
Methods : This research is an in vivo experimental study, pre- and post-test control group design, conducted in September and October 2022 at the Animal House Laboratory of the Faculty of Medicine, Sriwijaya University, and the Palembang Health Laboratory Center. There were 4 treatment groups: Group I, placebo; Group II, gentamicin-induced (GIG I) at 80 mg/kgBW; Group III, gentamicin-induced (GIG II) at 120 mg/kgBW; and Group IV, gentamicin-induced (GIG III) at 240 mg/kgBW. Gentamicin was administered intraperitoneally for 7 days, to 8 Wistar rats per group. Blood was taken from all Wistar rats in each group on days 0, 3, 7, and 14. The results of the study were tested for normality with the Shapiro-Wilk test and homogeneity with the Levene's test. The ANOVA test and the Post-Hoc test were used to conduct the analysis.
Results : Induction of gentamicin in the GIG I and GIG II groups was significant in increasing the mean creatinine and urea levels on day 0 and day 14 of treatment (p<0.05). In the GIG III group there was a 50% mortality in experimental animals showing a Lethal dose of 50 (LD50) at that dose.
Conclusion : GIG I and GIG II have significant nephrotoxic effects in increasing creatinine and urea levels which lead to renal fibrosi.
Downloads
References
1. Shamna, Jose J, . S, Ahmed R. A Brief Study of Nephrotoxicity and Nephroprotective Agents. Indian J Pharm Biol Res. 2020;8(01):09–13.
2. Binti Halim H, Achadiyani, Tjahjodjati. Nigella sativa Infusion as an Antioxidant Agent Against Gentamicin-Induced Kidney Damaged in Mice. Althea Med J. 2014 Dec 31;1(2):90–3.
3. Sales GTM, Foresto RD. Drug-induced nephrotoxicity. Vol. 66, Revista da Associacao Medica Brasileira. Associacao Medica Brasileira; 2020. p. 82–90.
4. Randjelović P, Veljković S, Stojiljković N, Sokolović D, Ilić I. Gentamicin nephrotoxicity in animals: Current knowledge and future perspectives. Vol. 16, EXCLI Journal. Leibniz Research Centre for Working Environment and Human Factors; 2017. p. 388–99.
5. Albino AH, Zambom FFF, Foresto-Neto O, Oliveira KC, Ávila VF, Arias SCA, et al. Renal Inflammation and Innate Immune Activation Underlie the Transition From Gentamicin-Induced Acute Kidney Injury to Renal Fibrosis. Front Physiol. 2021 Jul 7;12:606392.
6. Humphreys BD. Mechanisms of Renal Fibrosis. Annu Rev Physiol. 2018 Feb 10;80(1):309–26.
7. Administration O, Abu-basha E a, Al-shunnaq AF, Gehring R. Pharmacokinetics of Gentamicin C1 , C1a , C2 in Beagles after a Single Intravenous Dose. 2013;5(6):129–35.
8. Mullins ND, Deadman BJ, Moynihan HA, McCarthy FO, Lawrence SE, Thompson J, et al. The impact of storage conditions upon gentamicin coated antimicrobial implants. J Pharm Anal. 2016;6(6):374–81.
9. Wargo KA, Edwards JD. Aminoglycoside-induced nephrotoxicity. J Pharm Pract. 2014 Dec;27(6):573–7.
10. Towne TG. Aminoglycosides. Encycl Toxicol Third Ed. 2014 Jan 1;191–3.
11. Fauzi A, Titisari N, Sutarso, Mellisa V. Gentamicin Nephrotoxicity in Animal Model: Study of Kidney Histopathology and Physiological Functions. IOP Conf Ser Earth Environ Sci. 2020;465(1).
12. Nese A, Mert H, Yildirim S, Nihat M. The effect of fucoidan on changes of some biochemical parameters in nephrotoxicity induced by gentamicin in rats. Ankara Üniversitesi Vet Fakültesi Derg. 2018;65(1):9–14.
13. Ince S, Kucukkurt I, Demirel HH, Arslan-Acaroz D, Varol N. Boron, a Trace Mineral, Alleviates Gentamicin-Induced Nephrotoxicity in Rats. Biol Trace Elem Res. 2020;195(2):515–24.
14. Awodele O, Tomoye O, Quashie N, Ogunnowo S, Amagon K. Gentamicin nephrotoxicity: Animal experimental correlate with human pharmacovigilance outcome. Biomed J. 2015 Mar;38(2):125.
15. Adamson RH. The acute lethal dose 50 (LD50) of caffeine in albino rats. Regul Toxicol Pharmacol. 2016;80:274–6.
16. Basten G. Introduction to Clinical Interpreting Blood Results Introduction to Clinical Biochemistry Interpreting Blood Results. 2013.
17. Random D, Specimen S, Specimen H. Mosby’s Manual of Diagnostic and Laboratory Tests 6th Edition. Elsevier; 2017.
18. Levey AS, Eckardt KU, Dorman NM, Christiansen SL, Hoorn EJ, Ingelfinger JR, et al. Nomenclature for kidney function and disease: report of a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference. Kidney Int. 2020 Jun 1;97(6):1117–29.
19. Lusiana E, Tamzil NS, Oktarina D. The Efficacy of Cinnamon Extract ( Cinnamomum burmannii ) on Reducing Staging Acute Kidney Injury in Ischemia Reperfusion (IR) Model. Biosci Med J Biomed Transl Res. 2020;5(1).
20. Braun MM, Khayat M. Kidney Disease: Chronic Kidney Disease. FP Essent. 2021 Oct 1;509:20–5.
21. Gewin LS. Renal fibrosis: Primacy of the proximal tubule. Matrix Biol. 2018 Aug;68–69:248–62.
22. François H, Chatziantoniou C. Renal fibrosis: Recent translational aspects. Matrix Biol. 2018 Aug;68–69:318–32.
23. Zhan J, Liu M, Pan L, He L, Guo Y. Oxidative Stress and TGF-β1/Smads Signaling Are Involved in Rosa roxburghii Fruit Extract Alleviating Renal Fibrosis. Evid Based Complement Alternat Med. 2019 Aug 20;2019:4946580.
24. Ovadya Y, Krizhanovsky V. A new Twist in kidney fibrosis. Nat Med. 2015;21(9):975–7.
25. Thammitiyagodage MG, Silva NR De, Rathnayake C, Karunakaran R, Wgss K, Gunatillka MM. Biochemical and histopathological changes in Wistar rats after consumption of boiled and un-boiled water from high and low disease prevalent areas for chronic kidney disease of unknown etiology ( CKDu ) in north Central Province ( NCP ) and its comparison. 2020;3:1–12.
Additional Files
Published
How to Cite
Issue
Section
Citation Check
License
Copyright (c) 2023 Evi Lusiana, Irsan Saleh, Ernawati Sinaga, Zen Hafy
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Copyrights Notice
Copyrights:
Researchers publishing manuscrips at Medica Hospitalis: Journal of Clinical Medicine agree with regulations as follow:
Copyrights of each article belong to researchers, and it is likewise the patent rights
Researchers admit that Medica Hospitalia: Journal of Clinical Medicine has the right of first publication
Researchers may submit manuscripts separately, manage non exclusive distribution of published manuscripts into other versions (such as: being sent to researchers’ institutional repository, publication in the books, etc), admitting that manuscripts have been firstly published at Medica Hospitalia: Journal of Clinical Medicine
License:
Medica Hospitalia: Journal of Clinical Medicine is disseminated based on provisions of Creative Common Attribution-Share Alike 4.0 Internasional It allows individuals to duplicate and disseminate manuscripts in any formats, to alter, compose and make derivatives of manuscripts for any purpose. You are not allowed to use manuscripts for commercial purposes. You should properly acknowledge, reference links, and state that alterations have been made. You can do so in proper ways, but it does not hint that the licensors support you or your usage.
